Introduction. Idiopathic pulmonary fibrosis (IPF) is an independent risk factor for lung cancer development, and small cell lung\ncancer (SCLC) comprises 15-20% of lung cancers with IPF. The objective of this study was to investigate survival outcomes and\ntreatment-related complications according to GAP (gender, age, and physiology) stage in patients having SCLC with IPF (SCLCIPF).\nMaterials and Methods. Retrospectively collected data of SCLC-IPF patients from two tertiary care university hospitals in\nSouth Korea were reviewed. A total of 59 SCLC-IPF patients were identified and categorized according to GAP stage, which was\nproposed by Ley et al. in 2012 to predict the prognosis of IPF. Survival outcomes and treatment-related complications were compared\nbetween the two groups. Results. In a total of 59 patients, the median age was 71 years and 58 (98.3%) were male. In a comparison\nof themedian overall survival (OS) according to GAP stage,median OS of the advanced GAP stage group was significantly shorter\nthan median OS of GAP stage I group (7.1 months vs. 16.1 months; p = 0.002). Treatment-related complications occurred more\nfrequently in the advanced GAP stage group; advanced GAP stage was the only predictor that exhibited a significant association\nwith the incidence of acute exacerbation of IPF. Conclusions. Inferior survival outcome and higher incidence of treatment-related\npulmonary toxicities were noted in the advanced GAP stage group. Furthermore, advanced GAP stage was the only predictor of\ntreatment-related acute exacerbation of IPF. Physicians should thus consider GAP stage, which reflects the severity of IPF, during\ntreatment of SCLC-IPF.
Loading....